Cases & Deals

  • Home
  • Practices
  • AbbVie defeats IPR petition filed by Coherus challenging Humira®

Share

AbbVie defeats IPR petition filed by Coherus challenging Humira®

November 2016

Client(s) AbbVie Inc.

Jones Day successfully defended AbbVie Inc. in connection with an IPR petition brought by Coherus Biosciences, Inc. against U.S. Patent No. 9,114,166, which is directed to formulations for AbbVie's antibody therapeutic Humira®. Coherus sought to develop and commercialize a biosimilar version of Humira®. Following the filing of the Patent Owner's Preliminary Response by AbbVie, the PTAB denied institution of Coherus's IPR petition with regard to all of the challenged claims.

Coherus Biosciences Inc. v. AbbVie Biotechnology Ltd. et al., IPR2016-01018 (PTAB)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.